KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Receivables (2016 - 2025)

Historic Receivables for Sarepta Therapeutics (SRPT) over the last 15 years, with Q3 2025 value amounting to $524.4 million.

  • Sarepta Therapeutics' Receivables rose 469.16% to $524.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $524.4 million, marking a year-over-year increase of 469.16%. This contributed to the annual value of $636.6 million for FY2024, which is 4800.0% up from last year.
  • Latest data reveals that Sarepta Therapeutics reported Receivables of $524.4 million as of Q3 2025, which was up 469.16% from $600.6 million recorded in Q2 2025.
  • Sarepta Therapeutics' Receivables' 5-year high stood at $714.6 million during Q1 2025, with a 5-year trough of $133.3 million in Q1 2021.
  • For the 5-year period, Sarepta Therapeutics' Receivables averaged around $346.3 million, with its median value being $285.8 million (2023).
  • In the last 5 years, Sarepta Therapeutics' Receivables soared by 9736.12% in 2023 and then skyrocketed by 469.16% in 2025.
  • Quarter analysis of 5 years shows Sarepta Therapeutics' Receivables stood at $153.0 million in 2021, then surged by 42.44% to $217.9 million in 2022, then skyrocketed by 97.36% to $430.1 million in 2023, then surged by 48.0% to $636.6 million in 2024, then fell by 17.62% to $524.4 million in 2025.
  • Its Receivables was $524.4 million in Q3 2025, compared to $600.6 million in Q2 2025 and $714.6 million in Q1 2025.